The poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide suppresses cell growth and migration, enhancing suppressive effects of cisplatin in osteosarcoma cells

Oncology Reports

Volumn 25, Issue 5, 2011, Pages 1399-1405

  Zheng, Ya Dong ^a   Xu, Xi Qiang ^a   Peng, Fei ^a   Yu, Ji Zhe ^a   Wu, Hua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

3 aminobenzamide; Cisplatin; Human osteosarcoma; Poly (ADP ribose) polymerase

Indexed keywords

3 AMINOBENZAMIDE; CISPLATIN;

APOPTOSIS; ARTICLE; CELL INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MIGRATION INHIBITION; OSTEOSARCOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; OSTEOSARCOMA; POLY(ADP-RIBOSE) POLYMERASES;

EID: 79953040755     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1212     Document Type: Article

References (29)

1. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790, 2002. (Pubitemid 34111386)
2. Picci P, Ferrari S, Bacci G and Gherlinzoni F: Treatment recommendations for osteosarcoma and adult soft tissue sarcomas. Drugs 47: 82-92, 1994 (Pubitemid 24032379)
3. Kempf-Bielack B, Bielack SS, Jurgens H, et al: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23: 559-568, 2005 (Pubitemid 46224233)
4. Hayden JB and Hoang BH: Osteosarcoma: basic science and clinical implications. Orthop Clin North Am 37: 1-7, 2006. (Pubitemid 41719081)
5. Helleday T, Petermann E, Lundin C, Hodgson B and Sharma RA: DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8: 193-204, 2008. (Pubitemid 351301852)
6. Chambon P, Weill JD and Mandel P: Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 11: 39-43, 1963.
7. Sakamoto-Hojo ET and Balajee AS: Targeting poly (ADP) ribose polymerase I (PARP-1) and PARP-1 interacting proteins for cancer treatment. Anticancer Agents Med Chem 8: 402-416, 2008. (Pubitemid 351761425)
8. Peralta-Leal A, Rodriguez-Vargas JM, Aguilar-Quesada R, et al: PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med 47: 13-26, 2009.
9. Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S and Taniguchi T: Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol 37 223-227, 1991.
10. Hu JJ, Roush GC, Dubin N, Berwick M, Roses DF and Harris MN: Poly(ADP-ribose) polymerase in human breast cancer: a case-control analysis. Pharmacogenetics 7: 309-316, 1997. (Pubitemid 27356931)
11. Prasad SC, Thraves PJ, Bhatia KG, Smulson ME and Dritschilo A: Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing's sarcoma cells. Cancer Res 50: 38-43, 1990. (Pubitemid 20029990)
12. Shiobara M, Miyazaki M, Ito H, et al: Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 16: 338-344, 2001. (Pubitemid 32374852)
13. Masutani M, Nozaki T, Sasaki H, et al: Poly(ADP-ribose) polymerase-1 gene in human tumor cell lines: Its expression and structural alteration. Proc Japan Acad Ser B 80: 114-118, 2004. (Pubitemid 38572548)
14. Bryant HE and Helleday T: Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents. Biochem Soc Trans 32: 959-961, 2004. (Pubitemid 39655515)
15. Aguilar-Quesada R, Munoz-Gamez JA, Martin-Oliva D, et al: Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr Med Chem 14: 1179-1187, 2007. (Pubitemid 46739319)
16. Noel G, Godon C, Fernet M, Giocanti N, Megnin-Chanet F and Favaudon V: Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther 5: 564-574, 2006.
17. Tentori L, Leonetti C, Scarsella M, et al: Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J 20: 1709-1711, 2006.
18. Albert JM, Cao C, Kim KW, et al: Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 13: 3033-3042, 2007. (Pubitemid 46849580)
19. Donawho CK, Luo Y, Penning TD, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13: 2728-2737, 2007. (Pubitemid 46795129)
20. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917, 2005. (Pubitemid 40559005)
21. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921, 2005. (Pubitemid 40559006)
22. Rajesh M, Mukhopadhyay P, Batkai S, et al: Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem Biophys Res Commun 350: 352-357, 2006. (Pubitemid 44498642)
23. Tentori L, Lacal PM, Muzi A, et al: Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer 43: 2124-2133, 2007. (Pubitemid 47380363)
24. Pyriochou A, Olah G, Deitch EA, Szabo C and Papapetropoulos A: Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34 Int J Mol Med 22: 113-118, 2008.
25. Schreiber V, Dantzer F, Ame JC and de Murcia G: Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7: 517-528, 2006. (Pubitemid 44036457)
26. Martin-Oliva D, Aguilar-Quesada R, O'Valle F, et al: Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res 66: 5744-5756, 2006. (Pubitemid 43927128)
27. Huang SH, Xiong M, Chen XP, Xiao ZY, Zhao YF and Huang ZY: PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells. Oncol Rep 20: 567-572, 2008.
28. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE and Oltvai ZN: Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 4: 327-332, 1993. (Pubitemid 2028596)
29. Nguewa PA, Fuertes MA, Cepeda V, et al. Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. Med Chem 2: 47-53, 2006. (Pubitemid 44083165)